Alzheimer's Disease International (ADI)
News, blogs and stories from across the field of dementia, the work of Alzheimer’s Disease International and our members.
Lecanemab is the first therapy of its kind approved in the EU that could potentially slow the progression of Alzheimer’s disease. The use of lecanemab will now be considered by national payers, who will assess the treatment against further nationally determined criteria.
This comes as the Appeals board of the European Commission were unable to reach a verdict following the “no opinion” decision of the Standing Committee on Medicinal Products for Human Use and the European Commission. The matter will now be referred the European Commission for a final decision.
Phase II trial results found that donanemab slowed cognitive and functional decline in patients with early symptomatic Alzheimer's disease.
Lily Liu, a former communications professional in the non-profit sector, writes about her unique journey as an immigrant family caregiver in the United States and why she is a 'Dragon Daughter', even during the Year of the Ox.
Though Italy's National Dementia Plan was first approved in 2014, this is the first time that the plan will receive funding by the Italian government.
ADI 2020 will take place from Thursday, 10 December until Saturday, 12 December and feature over 1,500 delegates from around the world.
People with dementia must be included in the priority groups for new COVID-19 vaccines, both in care homes and at home, say Alzheimer’s Disease International People with dementia are being disproportionately affected by COVID-19 and amongst most vulnerable in society Recent studies show COVID-19 deaths disproportionately affecting people with dementia;…
Emma Cariaga and Ginny Warr of British Land explore what inclusive design means for older people and for business growth. They look at Canada Water, where British Land is creating London’s first new town centre in over 100 years, and at activities across the company’s wider portfolio.
A new policy briefing, co-authored by ADI, thoroughly examines dementia care policy in Qatar.
A new data platform AD Workbench was launched by the Alzheimer’s Disease Data Initiative (ADDI).